Adherence and persistence of single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens

Current Medical Research and Opinion

Volumn 26, Issue 12, 2010, Pages 2877-2887

  Zeng, F ^a   Patel, B V ^a   Andrews, L ^b   Frech Tamas, F ^b   Rudolph, A E ^b  

^a MedImpact Healthcare Systems Inc   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Angiotensin II receptor blockers; Antihypertensive Agents; Calcium channel blockers; Drug combinations; Patient adherence

Indexed keywords

ALMESARTAN PLUS AMLODIPINE; AMLODIPINE PLUS IRBESARTAN; AMLODIPINE PLUS LOSARTAN; AMLODIPINE PLUS OLMESARTAN; AMLODIPINE PLUS VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; COMPARATIVE STUDY; COST; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PILL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; TABLETS; YOUNG ADULT;

EID: 78349260029     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.534129     Document Type: Article

References (41)

1. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment and control of hypertension, 1988-2008. JAMA 2010;303:2043-50
2. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: Analysis of worldwide data. Lancet 2005;365:217-23
3. National Heart, Lung, and Blood Institute. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. August 2004. National Institute of Health. Available at: http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf. [Last accessed July 27, 2010]
4. Cushman WC. The burden of uncontrolled hypertension: morbidity and mortality associated with disease progression. J Clin Hypertens (Greenwich) 2003;5:14-22
5. Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (behazepril with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol 2000;86:1182-7
6. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mid to moderate essential hypertension. Clin Ther 2007;29:563-80
7. Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medox-omil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008;30:587-604
8. Destro M, Luckow A, Samson M, et al. Efficacy and safety of amlodipine/ valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multi-center study: the EX-EFFeCTS Study. J Am Soc Hypertens 2008;2:294-302
9. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326:1427
10. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002;62:443-62
11. Black HR. Triple fixed-dose combination therapy: back to the past. Hypertension 2009;54:19-22
12. Pimenta E, Oparil S. Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of olmesartan-amlodipine combination. Vasc Health Risk Manag 2008; 4:653-64
13. Nash DT. Rationale for combination therapy in hypertension management: focus on angiotensin receptor blockers and thiazide diuretics. South Med J 2007;100:386-92
14. Dusing R. Overcoming barrier to effective blood pressure control in patients with hypertension. Curr Med Res Opin 2006;22:1545-53
15. Cramer JA. Consequences of intermittent treatment for hypertension: the case for medication compliance and persistence. Am J Manag Care 1998; 4:1563-8
16. McCombs JS, Nichol MB, Newman CM, et al. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care 1994; 32:214-26
17. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43: 521-30
18. Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 1997;19:1446-57
19. Caro JJ, Speckman JL. Existing treatment strategies: does noncompliance make a difference? J Hypertens Suppl 1998;16:S31-4
20. Bramley TJ, Gerbino PP, Nightengale BS, et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006;12:239-45
21. Yeaw J, Breener JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15:728-40
22. Wogen J, Kreilick CA, Livornese RC, et al. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Manag Care Pharm 2003;9:424-9
23. Taylor AA, Schoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCI versus comparable component-based therapy. Congest Heart Fail 2003;9:324-32
24. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 2000;9(9 Suppl):2-6
25. Gerbino PP, Schoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm 2007;64:1279-83
26. Wang JG. A combine role of calcium channel blockers and angiotensin receptor blockers in stroke prevention. Vasc Health Risk Manag 2009;5:593-605
27. National Quality Forum. National Quality Forum endorses measures to improve medication safety and quality. August 17, 2009. Available at: http://www.qualityforum.org/News-And-Resources/Press-Releases/2009/ National-Quality-Forum-Endorses-Measures-to-Improve-Medication-Safety-and- Quality.aspx. [Last accessed July 27, 2010]
28. Pharmacy Quality Alliance. PQA Approved Measures. Available at: http://www.pqaalliance.org/files/PQA%20approved%20measures.pdf. [Last accessed July 27, 2010]
29. Vanderpoel DR, Hussein MA, Watson-Heidari T, et al. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis. Clin Ther 2004;26:2066-75
30. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165:1147-52
31. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med, 2006;166:1836-41
32. Patel BV, Remigio-Baker RA, Mehta D, et al. Effects of initial antihypertensive drug class on patient persistence and compliance in a usual-care setting in the United States. J Clin Hypertens (Greenwich) 2007;9:692-700
33. Patel BV, Remigio-Baker RA, Thiebaud P, et al. Improved persistence and adherence to diuretic fixed-dose combination therapy compared to diuretic monotherapy. BMC Fam Pract 2008;9:61
34. Fishman PA, Goodman MJ, Hornbrook MC, et al. Risk adjustment using automated ambulatory pharmacy data: the RxRisk model. Med Care 2003; 41:84-99
35. Zeng F, Chen C, Mastey V, et al. Utilization management for smoking cessation pharmacotherapy: varenicline rejected claims analysis. Am J Manag Care 2010;16: 667-84
36. Zeng F, An JJ, Scully R, et al. The impact of value-based benefit design on adherence to diabetes medications: a propensity score weighted difference in difference evaluation. Value Health 2010;13:846-52
37. D'Agostino Jr RB, D'Agostino Sr. RB, Estimating treatment effects using observational data. JAMA 2007;297:314-16
38. Rubin DB. Using propensity scores to help design observational studies: application to the tobacco litigation. Health Serv Outcomes Res Methodol 2001;2:169-88
39. Hirano K, Imbens GW. Estimation of causal effects using propensity score weighting: an application to data on right heart catheterization. Health Serv Outcomes Res Methodol 2001;2:259-78
40. Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med 2004;23:2937-60
41. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120:713-19